Recent Updates
Recently added Catalysts

Hydrocortisone granules

Phase 1

Adrenal Insufficiency | Small molecule | Endocrine |Neurocrine Biosciences, Inc.|Last Updated: Apr 26, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment14

FDA Designations

No designations recorded

Clinical trial landscape

Hydrocortisone granules · 1 trial · 1 indication

Phase 1 1
NCT01960530An Investigational Study of HydrocortisoneAdrenal Insufficiency
COMPLETED14 Analytics
PHASE1COMPLETED
An Investigational Study of Hydrocortisone
Adrenal InsufficiencyUnlock trial analytics

Study Endpoints

Primary Endpoints

Maximum Serum Concentration (Cmax)
Hourly from 0 to 24 hours

Derived PK for Serum Cortisol: Maximum serum concentration (Cmax)

AUC0-t
Hourly from 0 to 24 hours

Derived PK for Serum Cortisol: Area under the curve from 0-24 hours

Secondary Endpoints

Adverse Events (AEs)
Days 1-2 during each Study Period
Concentrations of Cortisol Binding Protein
Blood samples on Day 1 and/or Day 2 of each Study Period
Insulin Sensitivity Under Physiological Conditions and After Administration of Dexamethasone and Infacort®, Hydrocortisone Tablets and i.v Hydrocortisone.
Blood samples on Day 1 and/or Day 2 of each Study Period
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
Endogenous CortisolNO_INTERVENTIONNo Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
DexamethasoneOTHER1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
Infacort®EXPERIMENTAL20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
Hydrocortisone TabletACTIVE_COMPARATOR20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
i.v Hydrocortisone InjectionACTIVE_COMPARATOR20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.

Interventions

NameTypeDescription
Hydrocortisone granulesDRUGMulti-particulate granules
Hydrocortisone TabletDRUGStandard hydrocortisone tablets
i.v. Hydrocortisone InjectionDRUGStandard hydrocortisone solution for intravenous injection
DexamethasoneOTHERChallenge agent
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy male volunteers between 18 and 60 years of age, inclusive (at screening). * Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))\*2. * Subjects with no clinically significant abnormal serum biochemistry, haematology and urin...

Countries:United Kingdom
Unlock Eligibility Criteria